AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

MEDICLINIC INTERNATIONAL PLC

Director's Dealing Jun 10, 2020

4946_dirs_2020-06-10_84a5dbdf-57d3-4221-b2a4-9f526819fac6.html

Director's Dealing

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 4539P

Mediclinic International plc

10 June 2020

Mediclinic International plc

(Incorporated in England and Wales)

Company Number: 08338604

LSE Share Code: MDC

JSE Share Code: MEI

NSX Share Code: MEP

ISIN: GB00B8HX8Z88

LEI: 2138002S5BSBIZTD5I60

("Mediclinic", the "Company" or the "Group")

10 June 2020

NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

On 8 June 2020, Mr Jurgens Myburgh, Group Chief Financial Officer of Mediclinic International plc, acquired 7 500 shares in the Company at ZAR 63.94 per share. This purchase has been made in accordance with the Company's Remuneration Policy, whereby Mr Myburgh is required to maintain a minimum shareholding of 200% of his annual base compensation and until he has met that target, to purchase shares in the Company with 50% of the post-tax proceeds received from the deferred portion of awards made under the Short Term Incentive scheme and settled in cash. Mr Myburgh now owns a total of 90 500 shares in Mediclinic International plc.

The following notification is made in accordance with Articles 19.1 and 19.3 of the Market Abuse Regulation.

1.

Details of PDMR / persons closely associated with them ("PCA")

a)

Name

Mr Petrus Jurgens Myburgh

2.

Reason for the notification

a)

Position / status

Group Chief Financial Officer of the Company

b)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mediclinic International plc

b)

LEI

2138002S5BSBIZTD5I60

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification Code

Ordinary Shares

GB00B8HX8Z88

b)

Nature of the transaction

Purchase of shares

c)

Price(s) and volume(s)

Price(s) per share Volume(s)
ZAR 6388.00 386
ZAR 6388.00 364
ZAR 6388.00 500
ZAR 6389.00 1 321
ZAR 6389.00 500
ZAR 6393.00 268
ZAR 6395.00 500
ZAR 6396.00 500
ZAR 6400.00 500
ZAR 6400.00 1 052
ZAR 6400.00 1 609

d)

Aggregated information

Aggregated volume

Price

7 500

ZAR 63.94 per share

e)

Date of the transaction

8 June 2020; 09:26 UTC

f)

Place of the transaction

Johannesburg Stock Exchange

About Mediclinic International plc

Mediclinic is an international private healthcare services group, established in South Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates ("UAE").

The Group's core purpose is to enhance the quality of life.

Its vision is to be the partner of choice that people trust for all their healthcare needs.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its markets.

At 1 June 2020, Mediclinic comprised 76 hospitals, eight sub-acute and specialised hospitals, 15 day case clinics and 21 outpatient clinics. Hirslanden operated 17 hospitals, three day case clinics and three outpatient clinics in Switzerland with more than 1 800 inpatient beds; Mediclinic Southern Africa operations included 52 hospitals (three of which in Namibia), eight sub-acute and specialised hospitals and 10 day case clinics (four of which operated by Intercare) across South Africa, and more than 8 700 inpatient beds; and Mediclinic Middle East operated seven hospitals, two day case clinics and 18 outpatient clinics with more than 900 inpatient beds in the UAE.

The Company's primary listing is on the London Stock Exchange ("LSE") in the United Kingdom, with secondary listings on the JSE Ltd in South Africa and the Namibian Stock Exchange in Namibia.

Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group based in the United Kingdom and listed on the LSE.

For further information, please contact:

Company Secretary, Link Company Matters Limited

Caroline Emmet

+44 (0)20 7954 9548

Investor Relations, Mediclinic International plc

James Arnold, Head of Investor Relations

[email protected]

+44 (0)20 3786 8181

Media queries

FTI Consulting

Ben Atwell/Ciara Martin - UK

+44 (0)20 3727 1000

Sherryn Schooling - South Africa

+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom

Website: www.mediclinic.com 

Corporate broker: Morgan Stanley & Co International plc and UBS Investment Bank

JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)

NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

DSHBLGDLCXGDGGC

Talk to a Data Expert

Have a question? We'll get back to you promptly.